Use of propensity score technique to account for exposure-related covariates: An example and lesson

Medical Care

Volumn 45, Issue 10 SUPPL. 2, 2007, Pages

  Seeger, John D ^a,b   Kurth, Tobias ^b,c   Walker, Alexander M ^a,b  

^a Ingenix Inc   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cohort studies; Observational research; Propensity scores

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

COHORT ANALYSIS; CONFERENCE PAPER; CONTROL GROUP; EPIDEMIOLOGY; HEART INFARCTION; HUMAN; METHODOLOGY; OBSERVATION; PHARMACOEPIDEMIOLOGY; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS;

COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); CONTROL GROUPS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MATCHED-PAIR ANALYSIS; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; OBSERVATION; PHARMACOEPIDEMIOLOGY;

EID: 34848867584     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/mlr.0b013e318074ce79     Document Type: Article

References (20)

1. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
2. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333. (Pubitemid 29383480)
3. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763. (Pubitemid 27446562)
4. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics. 1996;52:249-264. (Pubitemid 26125107)
5. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511. (Pubitemid 29372891)
6. Maron DJ, Fazio S, Linton MRF. Current perspectives on statins. Circulation. 2000;101:207-213. (Pubitemid 30044262)
7. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol. 1998;82(Suppl J):3J-10J. (Pubitemid 28429253)
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
9. Shepherd J, Cobbe SM, Ford I, et al West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
10. Sacks FM, Pfeffer MA, Moye LA, et al Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009. (Pubitemid 26338729)
11. Downs JR, Clearfield M, Weis S, et al Air Force/Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622. (Pubitemid 28248586)
12. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
14. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Summary of the second report of the National Cholesterol Education Program (NCEP). JAMA. 1993;269:3015-3023.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486-2497.
16. Seeger JD, Walker AM, Williams PL, et al. A propensity score-matched cohort study of the effect of statin, mainly fluvastatin on the occurrence of acute myocardial infarction. Am J Cardiol. 2003;92:1447-1451. (Pubitemid 37532570)
17. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 2005;14:465-476. (Pubitemid 40990742)
18. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity score models. Am J Epidemiol. 2006;163:1149-1156. (Pubitemid 43987579)
19. Sturmer T, Schneeweiss S, Avorn J, et al. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005;162:279-289. (Pubitemid 41373532)
20. Kurth T, Walker AM, Glynn RJ, et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of non-uniform effect. Am J Epidemiol. 2006;163:262-270. (Pubitemid 43145754)